16:22 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
19:21 , Jun 20, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Photothermal-activated nanoparticles could be used for sequential delivery of chemotherapy and photothermal therapy for cancer. The nanoparticles consist of an inner porous silica shell containing a palladium (II)-based photothermal agent which emits heat in...
20:35 , Jun 6, 2018 |  BC Innovations  |  Translation in Brief

Distinguishing DLBCL

A genomics-based method of subtyping diffuse large B cell lymphoma could improve prognostic predictions and identification of subtype-appropriate treatment regimens. Diffuse large B cell lymphoma (DLBCL) is clinically and genetically heterogeneous and roughly 40% of patients...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports updated Phase Ib/II data for ovarian cancer candidate

ImmunoGen Inc. (NASDAQ:IMGN) reported updated data from the Phase Ib/II FORWARD II trial evaluating mirvetuximab soravtansine (IMGN853) to treat folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer. The data were released in an abstract...
15:22 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample and cell culture studies suggest inhibiting BARD1, BRCA1, CDK1 or CKD12 could help treat tamoxifen-resistant breast cancer. In tumor tissue from 27 recurrent breast cancer patients whose tumors became resistant...
21:53 , Apr 17, 2018 |  BC Extra  |  Politics & Policy

Australia to evaluate Lilly's Lartruvo under new provisional pathway

Australia's Therapeutic Goods Administration (TGA) said soft tissue sarcoma drug Lartruvo olaratumab from Eli Lilly and Co. (NYSE:LLY) was granted provisional approval determination, making the drug eligible for review under the country's new provisional approval...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
17:30 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports Phase Ib/II data for mirvetuximab soravtansine plus Keytruda in ovarian cancer

ImmunoGen Inc. (NASDAQ:IMGN) reported data from 14 evaluable heavily pretreated folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer patients in the dose-escalation portion of the Phase Ib/II FORWARD II trial showing that mirvetuximab soravtansine...
23:15 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Tissue markers Tumor levels of phosphorylated MEF2C could help predict responses to chemotherapy in AML. In 47 patients treated with chemotherapy, high tumor levels of S222-phosphorylated MEF2C were associated with chemotherapy resistance and poor survival....
20:22 , Mar 15, 2018 |  BC Extra  |  Clinical News

Adapting T cell manufacturing methods could improve CAR Ts

Researchers at The Children's Hospital of Philadelphia identified key factors that affect the potential of T cells from pediatric patients with leukemias, lymphomas and sarcomas to be modified into effective CAR T cell therapies. The...